Over the past decade, CMS actuaries have consistently overestimated future healthcare spending. They failed to foresee the great moderation that in fact took place.
Among all the proffered panaceas for reducing America's high healthcare costs, price transparency is the least likely to make a major dent in the problem.
Policymakers and regulators have not fully considered the consequences of and public reaction to transforming short-term plans from a stop-gap measure to a substitute for more comprehensive plans provided through the Affordable Care Act.
Regarding the story "CMS actuary predicts GOP repeal bill will reduce coverage by 13 million" (ModernHealthcare.com, June 13), with the increasing number of plans that offer horrific coverage for care (catastrophic coverage designs, for example), it is somewhat unfair to simply state a lost coverage number.
Other populous states should take a close look at what California is doing. Smaller states may want to form compacts with their neighbors to pursue something similar. Gov. Gavin Newsom has offered a practical approach to achieving more reasonable drug pricing.
Ascension recently split the title of president and CEO and unified its two-pronged structure. That will result in the upcoming departure of three top executives including Patricia Maryland, who has been at Ascension for 15 years.